RFK Jr. Just Supercharged These 2 Biotech Penny Stocks
SGMO and EDIT are set to benefit from RFK Jr.’s plans to fast-track the review of drugs targeting rare diseases.
Barchart ·
Get all your news in one place.
100's of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100's of premium titles. One news app.
FORGOTTEN HISTORY: Sangamo | History Defined
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
Amgen (NASDAQ:AMGN) announced top-line results from the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS (sotorasib) in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), the study met primary endpoint. Amgen shares traded in a range of $238.29 to $240.31 on day volume of 2.43 million shares, closed regular…
Benzinga ·
Sangamo Therapeutics Shares Updated Interim Data From Fabry Disease Gene Therapy Trial
Sangamo Therapeutics Inc (NASDAQ: SGMO)
Benzinga ·
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Coverage From
Benzinga
Barchart
Organisations
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Topics
Read news from The Economist, FT, and more,
with one subscription
with one subscription
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.
100+ trusted global sources.
